[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_f6542785-0373-44d7-8248-31871b8eb84b":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:f6542785-0373-44d7-8248-31871b8eb84b,\"}":92},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":29,"indexDatabases":53,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},"f6542785-0373-44d7-8248-31871b8eb84b","2023-12-05T06:57:46.215+00:00","2025-11-21T10:06:04.454+00:00",[],"The-American-Journal-of-the-Medical-Sciences",{"issn":12,"title":14},{"VOID":13},"00029629",{"EN":15},"The American Journal of the Medical Sciences","PUBLISHER","PENDING",null,0,[21],{"id":22,"createTime":23,"updateTime":24,"relativeEntities":25,"label":26,"description":28,"parentId":18,"standard":18,"scholarHubFieldId":18},"0254e3e5-c28d-4a33-83da-81bc94d29ffd","2023-05-29T10:24:00.931+00:00","2023-11-21T07:56:41.438+00:00",[],{"EN":27},"Medicine (miscellaneous)",{},[30,42],{"id":31,"createTime":32,"updateTime":33,"relativeEntities":34,"slug":35,"properties":36,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":40,"url":18,"parentIds":41,"statistic":18},"34432dfd-8a81-4cb8-a3f5-0ee8b74bbd54","2023-05-29T10:24:05.014+00:00","2025-11-21T10:07:46.877+00:00",[],"Lippincott-Williams-and-Wilkins-Ltd-",{"title":37},{"EN":38},"Lippincott Williams and Wilkins Ltd.","AFFILIATION",5,[],{"id":43,"createTime":44,"updateTime":45,"relativeEntities":46,"slug":47,"properties":48,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":51,"url":18,"parentIds":52,"statistic":18},"88620e1c-4e83-45c7-9895-c9773cdc5cb4","2023-05-29T12:06:08.191+00:00","2023-12-20T08:29:46.587+00:00",[],"ELSEVIER-SCIENCE-INC",{"title":49},{"EN":50},"ELSEVIER SCIENCE INC",30,[],[54,73],{"id":55,"indexDatabase":56,"url":70,"indexYears":18,"academicFieldIds":71,"indexDatabaseRanking":18},"10602876-10e5-4bb3-a02c-731b40fc58f3",{"id":57,"createTime":58,"updateTime":59,"relativeEntities":60,"label":61,"description":63,"key":66,"publicationTags":67,"standard":18},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":62,"VI":62},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":64,"EN":65},"Cơ sở dữ liệu SCIE","SCIE database","scie",[68,69],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0002-9629",[72],"c796e0e3-2c7c-4993-b16f-e2f1a695268e",{"id":74,"indexDatabase":75,"url":87,"indexYears":88,"academicFieldIds":89,"indexDatabaseRanking":91},"ff38dc89-226f-40e9-8c20-7fd7b399df80",{"id":76,"createTime":77,"updateTime":78,"relativeEntities":79,"label":80,"description":82,"key":84,"publicationTags":85,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":81,"VI":81},"Scopus - Elsevier",{"EN":81,"VI":83},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[86],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F27086","1945-2025",[90],"e89cebf4-fecf-4b74-8ab4-88fca891e4c2","SCOPUS__Q2",{"meta":93,"data":95},{"total":94},"2945",[96,188,311,409,469,535,581,643,749,801],{"id":97,"createTime":98,"updateTime":99,"relativeEntities":100,"slug":101,"properties":102,"entityType":109,"verifyStatus":110,"verifyTime":99,"verifyNote":111,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":112,"fullTextUrl":18,"authors":113,"publicationType":156,"publisherRelationship":157,"citationCount":18,"citationInfo":18,"publishDate":185,"publishYear":186,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"a0c1d64b-dc7b-4217-a214-0d68bd205c9e","2024-01-04T19:07:07.222+00:00","2025-01-25T23:59:27.224+00:00",[],"Developing-Theoretical-Constructs-for-Outcomes-Research",{"references":103,"title":105,"doi":107},{"VOID":104},"The President's Advisory Commission on Consumer Protection, and Quality in the Health Care Industry. Quality first: better health care for all Americans. Washington (DC): US Government Printing Office, 1998. (Also available at http:\u002F\u002Fwww.hcqualitycommission.gov\u002Ffinal\u002F)\nGoldberg, 1994, Conducting medical effectiveness research: a report from the inter-PORT work groups, Med Care, 32, JS1\nFeinstein, 1983, An additional basic science for clinical medicine: II. The limitations of randomized trials, Ann Intern Med, 99, 544, 10.7326\u002F0003-4819-99-4-544\nGuadagnoli, 1994, Outcomes research: hope for the future or the latest rage?, Inquiry, 31, 14\nBrook, 1987, Monitoring quality of care in the Medicare program, JAMA, 258, 3138, 10.1001\u002Fjama.1987.03400210080030\nWennberg, 1980, The need for assessing the outcome of common medical practices, Annu Rev Public Health, 1, 277, 10.1146\u002Fannurev.pu.01.050180.001425\nSchroeder, 1990, Outcome assessment 70 years later. Are we ready?, N Engl J Med, 316, 160, 10.1056\u002FNEJM198701153160309\nEllwood, 1988, Shattuck lecture—outcomes management. A technology of patient experience, N Engl J Med, 318, 1549, 10.1056\u002FNEJM198806093182329\nRoper, 1988, Effectiveness in health care. An initiative to evaluate and improve medical practice, N Engl J Med, 319, 1197, 10.1056\u002FNEJM198811033191805\nRelman, 1988, Assessment and accountability. The third revolution in medical care, N Engl J Med, 319, 1220, 10.1056\u002FNEJM198811033191810\nEpstein, 1990, The outcomes movement—will it get us where we want to go?, N Engl J Med, 323, 266, 10.1056\u002FNEJM199007263230410\nAnderson, 1994, Measuring what works in health care, Science, 263, 1080, 10.1126\u002Fscience.8108722\nCockrane, 1971\nD'Agnostino, 1995, Measuring effectiveness. What to expect without a randomized control group, Med Care, 33, AS95\n1997\nSchwartz, 1990, Assessment of medical outcomes. New opportunities for achieving a long sought-after objective, Int J Technol Assess Health Care, 6, 333, 10.1017\u002FS0266462300000866\nNeuhauser, 1990, Ernest Amory Codman, MD, and end results of medical care, Int J Technol Assess Health Care, 6, 307, 10.1017\u002FS0266462300000842\nCodman, 1917\nLembcke, 1952, Measuring, the quality of medical care through vital statistics based on hospital service areas: 1. Comparative study of appendectomy rates, Am J Public Health, 42, 276, 10.2105\u002FAJPH.42.3.276\nWennberg, 1973, Small area variations in health care delivery, Science, 182, 1102, 10.1126\u002Fscience.182.4117.1102\nBrook, 1989\nChassin, 1989\nDonabedian, 1980\nMcAuliffe, 1979, Measuring, the quality of medical care: process versus outcome, Milbank Mem Fund Q, 57, 118, 10.2307\u002F3349751\nBrook, 1973\nFessel, 1972, Assessing quality of care from the medical record, N Engl J Med, 286, 134, 10.1056\u002FNEJM197201202860305\nGreenfield, 1977, The clinical investigation and management of chest pain in an emergency department: quality assessment by criteria mapping, Medical Care, 15, 898, 10.1097\u002F00005650-197711000-00003\nKane, 1976, Measuring outcomes of care in an ambulatory primary case population: a pilot study, J Community Health, 1, 233, 10.1007\u002FBF01324582\nLindsay, 1976, Quality- of-care assessment. I. Outpatient management of acute bacterial cystitis as the model, Mayo Clin Proc, 51, 307\nNobrega, 1977, Quality assessment in hypertension: analysis of process and outcome methods, N Engl J Med, 296, 145, 10.1056\u002FNEJM197701202960305\nRomm, 1976, Correlates of outcomes in patients with congestive heart failure, Med Care, 14, 765, 10.1097\u002F00005650-197609000-00004\nRubenstein, 1977, Quality-of-care assessment by process and outcome scoring, Ann Intern Med, 86, 617, 10.7326\u002F0003-4819-86-5-617\nStarfield, 1972, Effectiveness of pediatric care: the relationship between processes and outcome, Pediatrics, 49, 547, 10.1542\u002Fpeds.49.4.547\nPublic Law 101–239. Omnibus Budget Reconciliation Act of 1989. Washington (DC): United States Congress; 1989. Amendment of the Public Health Service Act (42 U.S.C. 201 et seq.), Section 1142 (b).\nMcCormick, 1997, The role of the Agency for Health Care Policy and Research in improving outcomes of care, Nurs Clin North Am, 32, 521\nClancy, 1997, Outcomes research at the Agency for Health Care Policy and research, Dis Manag Clin Outcomes, 3, 72, 10.1016\u002FS1088-3371(98)80003-X\nMaklan, 1994, Methodological challenges and innovations in patient outcomes research, Med Care, 32, JS13\nFowler, 1994, Methodological issues in measuring patient-reported outcomes: the agenda of the work group on outcomes assessment, Med Care, 32, JS65\nDeyo, 1995, Promises and limitations of the patient outcomes research teams: the low back pain example, Proc Assoc Am Physicians, 107, 2\nBernard, 1957\nKerlinger, 1986\nDe Poy, 1993\nLipsey, 1990, Theory as method: small theories of treatments, 33\nEvans, 1990, Producing health, consuming health care, Soc Sci Med, 31, 1347, 10.1016\u002F0277-9536(90)90074-3\nStarfield, 1973, Health services research: a working model, N Engl J Med, 289, 132, 10.1056\u002FNEJM197307192890305\nInstitute of Medicine, 1979\nAntonovsky, 1967, Social class, life expectancy and overall mortality, Milbank Mem Fund Q, 45, 31, 10.2307\u002F3348839\nFeinstein, 1993, The relationship between socioeconomic status and health: a review of the literature, Milbank Q, 71, 279, 10.2307\u002F3350401\nFrank, 1994, The determinants of health from a historical perspective, Daedalus, 123, 1\nHahn, 1995, No insurance, public insurance: do these options contribute to differences in general health?, J Health Care Poor Underserved, 6, 41, 10.1353\u002Fhpu.2010.0333\n1992\nPalank, 1991, Determinants of health-promotive behavior. A review of current research, Nurs Clin North Am, 26, 815\nCoyle, 1999, Using antecedents of medical care to develop valid quality of care measures, Int J Qual Health Care, 11, 5, 10.1093\u002Fintqhc\u002F11.1.5",{"EN":106},"Developing Theoretical Constructs for Outcomes Research",{"VOID":108},"10.1016\u002Fs0002-9629(15)40737-2","PUBLICATION","VERIFIED","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0002962915407372",[114,131,144],{"id":115,"sortIndex":116,"researcher":18,"roles":117,"affiliations":119,"properties":128},"36595857-a9db-4d0b-a41f-afa669aedcc6",1,[118],"AUTHOR",[120],{"id":18,"sortIndex":19,"affiliation":121,"properties":18},{"id":122,"createTime":123,"updateTime":123,"relativeEntities":124,"slug":18,"properties":125,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"f3993683-fc58-489a-ba69-80b553faf406","2024-01-04T19:07:07.272+00:00",[],{"title":126},{"VI":127},"Division of General Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas USA",{"title":129},{"VI":130},"Biff F. Palmer",{"id":132,"sortIndex":133,"researcher":18,"roles":134,"affiliations":135,"properties":141},"764caa6f-3425-4da8-a5e5-be5f5ed9d706",2,[118],[136],{"id":18,"sortIndex":19,"affiliation":137,"properties":18},{"id":122,"createTime":123,"updateTime":123,"relativeEntities":138,"slug":18,"properties":139,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":140},{"VI":127},{"title":142},{"VI":143},"Yvonne M. Coyle",{"id":145,"sortIndex":19,"researcher":18,"roles":146,"affiliations":147,"properties":153},"a59481f0-1f3f-413f-a545-e3737288e948",[118],[148],{"id":18,"sortIndex":19,"affiliation":149,"properties":18},{"id":122,"createTime":123,"updateTime":123,"relativeEntities":150,"slug":18,"properties":151,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":152},{"VI":127},{"title":154},{"VI":155},"Norman M. Kaplan","ARTICLE",{"url":112,"publisher":158,"properties":180},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":159,"slug":10,"properties":160,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":163,"manageAffiliations":164,"indexDatabases":165,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":161,"title":162},{"VOID":13},{"EN":15},[],[],[166,173],{"id":74,"indexDatabase":167,"url":87,"indexYears":88,"academicFieldIds":172,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":168,"label":169,"description":170,"key":84,"publicationTags":171,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":174,"url":70,"indexYears":18,"academicFieldIds":179,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":175,"label":176,"description":177,"key":66,"publicationTags":178,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":181,"pages":183},{"VOID":182},"319",{"VOID":184},"245-249","2000-04-01",2000,false,{"id":189,"createTime":190,"updateTime":190,"relativeEntities":191,"slug":18,"properties":192,"entityType":109,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":199,"fullTextUrl":18,"authors":200,"publicationType":156,"publisherRelationship":281,"citationCount":18,"citationInfo":18,"publishDate":309,"publishYear":310,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"ac42575d-dce5-4654-bf14-022dc21de231","2024-02-08T23:58:44.236+00:00",[],{"references":193,"title":195,"doi":197},{"VOID":194},"Berger, 1969, IgA glomerular deposits in renal diseases, Transplant Proc, 1, 939\nTomino, 1982, Detection of polymeric IgA in glomeruli from patients with IgA nephropathy, Clin Exp Immunol, 49, 419\nTomino, 1982, Specificity of eluted antibody from renal tissues of patients with IgA nephropathy, Amer J Kidney Dis, 1, 276, 10.1016\u002FS0272-6386(82)80025-5\nKozbor, 1983, The production of monoclonal antibodies from human lymphocytes, Immunology Today, 4, 72, 10.1016\u002F0167-5699(83)90123-8\nMaeda-Takekoshi, 1984, Transformation of human colostrum lymphocytes with Epstein-Barr virus and the production of IgA in culture, Tokai J Exp Clin Med, 9, 103\nYagame, 1989, Discriminant analysis of clinical markers before renal biopsy in patients with IgA nephropathy, Japn J Nephrol, 31, 735\nTomino, 1981, Evaluation of the staining conditions of immunofluorescence in primary glomerulonephritis, Acta Pathol Jpn, 31, 99\nFaith, 1982, ELISA assays for IgM and IgG rheumatoid factors, J Immunol Methods, 55, 169, 10.1016\u002F0022-1759(82)90029-1\nLowance, 1973, Immunoglobulin A (IgA) associated glomerulonephritis, Kidney Int, 3, 167, 10.1038\u002Fki.1973.25\nEndoh, 1984, In vivo alteration of antibody production in patients with IgA nephropathy, Clin Exp Immunol, 57, 564\nNagy, 1984, Herpes virus antigens and antibodies in kidney biopsies and sera of IgA glomerulonephritic patients, Clin Nephrol, 21, 259\nWu, 1988, Epstein-Barr virus specific antibodies in patients with IgA nephropathy, Sing Med J, 29, 257",{"EN":196},"Preliminary Study on Specificity of IgA Released from Lymphocytes by EB Virus Transformation in Patients with IgA Nephropathy",{"VOID":198},"10.1097\u002F00000441-199006000-00004","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS000296291536095X",[201,216,234,246,262],{"id":202,"sortIndex":133,"researcher":18,"roles":203,"affiliations":204,"properties":213},"c64a70e5-6b77-43f1-868e-65c7f5bc726d",[118],[205],{"id":18,"sortIndex":19,"affiliation":206,"properties":18},{"id":207,"createTime":208,"updateTime":208,"relativeEntities":209,"slug":18,"properties":210,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"3f95479b-9e04-4f42-9f6a-9a34a4c0a1f5","2024-02-08T23:58:44.280+00:00",[],{"title":211},{"VI":212},"Division of Nephrology and Metabolism, Department of Internal Medicine, Tokai University, Kanagawa-Ken 259-11, Japan.",{"title":214},{"VI":215},"Mitsunori Yagame",{"id":217,"sortIndex":218,"researcher":18,"roles":219,"affiliations":220,"properties":231},"ba3744d5-1134-409e-add6-91922445b788",4,[118],[221],{"id":18,"sortIndex":19,"affiliation":222,"properties":18},{"id":223,"createTime":224,"updateTime":225,"relativeEntities":226,"slug":227,"properties":228,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"0103a690-d093-49aa-abae-75d0b1b1f7b4","2024-01-04T04:34:02.770+00:00","2025-06-11T14:29:34.204+00:00",[],"Division-of-Nephrology-Department-of-Medicine-Juntendo-University-School-of-Medicine-2-1-1-Hongo-Bunkyo-Ku-Tokyo-113-Japan",{"title":229},{"VI":230},"Division of Nephrology, Department of Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, 113, Japan",{"title":232},{"VI":233},"Shigeaki Tanaka",{"id":235,"sortIndex":116,"researcher":18,"roles":236,"affiliations":237,"properties":243},"3c1dad8a-e6b6-4d17-85d1-b82c34a7a2eb",[118],[238],{"id":18,"sortIndex":19,"affiliation":239,"properties":18},{"id":223,"createTime":224,"updateTime":225,"relativeEntities":240,"slug":227,"properties":241,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":242},{"VI":230},{"title":244},{"VI":245},"Hikaru Koide",{"id":247,"sortIndex":248,"researcher":18,"roles":249,"affiliations":250,"properties":259},"8d1e5835-7cef-4cf7-9de5-e76145d8cf58",3,[118],[251],{"id":18,"sortIndex":19,"affiliation":252,"properties":18},{"id":253,"createTime":254,"updateTime":254,"relativeEntities":255,"slug":18,"properties":256,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"3a9c394a-d633-4aef-8c23-4cdda31b7a1f","2024-02-08T23:58:44.292+00:00",[],{"title":257},{"VI":258},"Department of Molecular Biology, School of Medicine, Tokai University, Kanagawa-Ken 259-11, Japan.",{"title":260},{"VI":261},"Hideto Sakai",{"id":263,"sortIndex":19,"researcher":18,"roles":264,"affiliations":265,"properties":278},"f3520ee9-e2c6-40ae-b646-591fe5068b3c",[118],[266],{"id":267,"sortIndex":19,"affiliation":268,"properties":275},"d72f0036-8ff5-4bf5-810c-e09483d7fcbf",{"id":269,"createTime":270,"updateTime":270,"relativeEntities":271,"slug":18,"properties":272,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"dd719002-f1e9-4ee8-81ad-20c2bf897319","2024-01-28T10:04:17.710+00:00",[],{"title":273},{"VI":274},"Division of Nephrology, Department of Medicine, Juntendo University School of Medicine, 2–1-1 Hongo, Bunkyo-Ku, Tokyo 113, Japan",{"title":276},{"VI":277},"Division of Nephrology, Department of Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113, Japan",{"title":279},{"VI":280},"Yasuhiko Tomino",{"url":199,"publisher":282,"properties":304},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":283,"slug":10,"properties":284,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":287,"manageAffiliations":288,"indexDatabases":289,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":285,"title":286},{"VOID":13},{"EN":15},[],[],[290,297],{"id":74,"indexDatabase":291,"url":87,"indexYears":88,"academicFieldIds":296,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":292,"label":293,"description":294,"key":84,"publicationTags":295,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":298,"url":70,"indexYears":18,"academicFieldIds":303,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":299,"label":300,"description":301,"key":66,"publicationTags":302,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":305,"pages":307},{"VOID":306},"299",{"VOID":308},"374-378","1990-06-01",1990,{"id":312,"createTime":313,"updateTime":314,"relativeEntities":315,"slug":316,"properties":317,"entityType":109,"verifyStatus":110,"verifyTime":314,"verifyNote":111,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":324,"fullTextUrl":18,"authors":325,"publicationType":156,"publisherRelationship":379,"citationCount":18,"citationInfo":18,"publishDate":407,"publishYear":408,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"eed53892-066a-40a8-a104-04a4cf21baed","2023-12-28T05:26:31.582+00:00","2025-01-23T23:58:43.813+00:00",[],"Induction-of-Cardiac-Insulin-Like-Growth-Factor-I-Gene-Expression-in-Pressure-Overload-Hypertrophy",{"references":318,"title":320,"doi":322},{"VOID":319},"Izumo, 1987, Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone infused signals, J Clin Invest, 79, 971, 10.1172\u002FJCI112908\nIzumo, 1988, Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload, Proc Natl Acad Sci U S A, 85, 339, 10.1073\u002Fpnas.85.2.339\nLund, 1986, Somatomedin-C\u002Finsulin-like growth factor-I and insulin-like growth factor-II mRNAs in rat fetal and adult tissues, J Biol Chem, 261, 14539, 10.1016\u002FS0021-9258(18)66903-0\nD’Ercole, 1984, Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action, Proc Natl Acad Sci U S A, 81, 935, 10.1073\u002Fpnas.81.3.935\nSara, 1990, Insulin-like growth factors and their binding proteins, Physiol Reu, 70, 591, 10.1152\u002Fphysrev.1990.70.3.591\nEngelmann, 1989, Insulin-like growth factors and neonatal cardiomyocyte development: Ventricular gene expression and membrane receptor variations in normotensive and hypertensive rats, Mol Cell Endocrinol, 63, 1, 10.1016\u002F0303-7207(89)90076-2\nHan, 1988, Expression of somatomedin\u002Finsulin-like growth factor messenger ribonucleic acids in the human fetus: Identification, characterization, and tissue distribution, J Clin Endocrinol Metab, 66, 422, 10.1210\u002Fjcem-66-2-422\nHan, 1987, Cellular localization of Somatomedin (Insulin-Like growth factor) messenger RNA in the human fetus, Science, 236, 193, 10.1126\u002Fscience.3563497\nBeck, 1987, Histochemical localization of IGF-I and -II mRNA in the developing rat embryo, Development, 101, 175, 10.1242\u002Fdev.101.1.175\nD’Ercole, 1986, Tissue and plasma somatomedin-C\u002Finsulin-like growth factor I concentrations in the human fetus during the first half of gestation, Pediatr Res, 20, 253, 10.1203\u002F00006450-198603000-00011\nSchoenle, 1982, Insulin-Like growth factor I stimulates growth in hypophysectomized rats, Nature, 296, 252, 10.1038\u002F296252a0\nLowe, 1989, Regulation by fasting of rat insulin-like growth factor I and its receptor, J Clin Invest, 84, 619, 10.1172\u002FJCI114207\nHansson, 1987, Regenerating endothelial cells express insulin-like growth factor-I immunoreactivity after arterial injury, Cell Tissue Res, 250, 499, 10.1007\u002FBF00218940\nCercek, 1990, Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation, Circ Res, 66, 1755, 10.1161\u002F01.RES.66.6.1755\nTurner, 1988, Induction of mRNA for IGF-I and -II during growth hormone-stimulated muscle hypertrophy, Am J Physiol, 255, E513\nNair, 1968, Biochemical correlates of cardiac hypertrophy. I. Experimental model; changes in heart weight, RNA content, and nuclear RNA polymerase activity, Circ Res, 23, 451, 10.1161\u002F01.RES.23.3.451\nChirgwin, 1979, Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease, Biochemistry, 5294, 10.1021\u002Fbi00591a005\nAviv, 1972, Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose, Proc Natl Acad U S A, 69, 1408, 10.1073\u002Fpnas.69.6.1408\nMurphy, 1987, Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I, Endocrinology, 121, 684, 10.1210\u002Fendo-121-2-684\nMelton, 1984, Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter, Nucleic Acids Res, 2, 7035, 10.1093\u002Fnar\u002F12.18.7035\nRotwein, 1988, Differential expression of insulin-like growth factor genes in rat central nervous system, Proc Natl Acad Sci U S A, 85, 265, 10.1073\u002Fpnas.85.1.265\nFort, 1985, Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family, Nucleic Acids Res, 13, 1431, 10.1093\u002Fnar\u002F13.5.1431\nMorgan, 1987, Biochemical mechanisms of cardiac hypertrophy, Annu Rev Physiol, 49, 533, 10.1146\u002Fannurev.ph.49.030187.002533\nTaylor, 1990, Pressure induces insulin-like growth factor I secretion by endothelial cells (abstract), Hypertension, 16, 335A\nDelafontaine, 1991, Insulin-like growth factor I gene expression in vascular cells, Hypertension, 17, 693, 10.1161\u002F01.HYP.17.5.693\nFath, 1993, Abdominal coarctation increases insulin-like growth factor I mRNA levels in rat aorta, Circ Res, 72, 271, 10.1161\u002F01.RES.72.2.271\nSara, 1980, Serum levels of immunoreactive somatomedin A in the rat: Some developmental aspects, Endocrinology, 107, 622, 10.1210\u002Fendo-107-2-622\nYee, 1990, Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation, J Clin Invest, 86, 1806, 10.1172\u002FJCI114910\nStiles, 1985, Relation of kidney tissue somatomedin C\u002Finsulin-like growth factor I to postnephrectomy renal growth in the rat, Endocrinology, 117, 2397, 10.1210\u002Fendo-117-6-2397\nFagin, 1987, Relative increase in insulin-like growth factor I messenger ribonucleic acid levels in compensatory renal hypertrophy, Endocrinology, 120, 718, 10.1210\u002Fendo-120-2-718\nKomuro, 1990, Molecular cloning of gene sequences from rat heart rapidly responsive to pressure overload, Circ Res, 66, 979, 10.1161\u002F01.RES.66.4.979\nBohler, 1988, Cardiac response to pressure overload in the rat: The selective alteration of in vitro directed RNA translation products, Circ Res, 63, 448A, 10.1161\u002F01.RES.63.2.448\nCzerwinski, 1990, Modulation of insulinlike growth factor-I mRNA during cardiac hypertrophy (abstract), FASEB J, 4, 2066\nDonohue, 1990, Sequential induction of cardiac c-myc and insulin-like growth factor-I gene expression in response to elevated left ventricular afterload (abstract), Clin Res, 38, 240A",{"EN":321},"Induction of Cardiac Insulin-Like Growth Factor I Gene Expression in Pressure Overload Hypertrophy",{"VOID":323},"10.1097\u002F00000441-199308000-00001","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0002962915354525",[326,343,355,367],{"id":327,"sortIndex":248,"researcher":18,"roles":328,"affiliations":329,"properties":340},"2a6c1626-7da9-414c-b3fb-3c73b858e130",[118],[330],{"id":18,"sortIndex":19,"affiliation":331,"properties":18},{"id":332,"createTime":333,"updateTime":334,"relativeEntities":335,"slug":336,"properties":337,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"b94676b9-133e-4621-a134-18e200e23481","2023-12-06T13:49:39.144+00:00","2024-09-25T22:30:35.308+00:00",[],"Division-of-Cardiology-Department-of-Medicine-Emory-University-School-of-Medicine-Atlanta-Georgia",{"title":338},{"VI":339},"Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia",{"title":341},{"VI":342},"P. Delafontaine",{"id":344,"sortIndex":116,"researcher":18,"roles":345,"affiliations":346,"properties":352},"6c9c1691-0eb9-42c2-ab13-03659303a572",[118],[347],{"id":18,"sortIndex":19,"affiliation":348,"properties":18},{"id":332,"createTime":333,"updateTime":334,"relativeEntities":349,"slug":336,"properties":350,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":351},{"VI":339},{"title":353},{"VI":354},"Kenneth A. Fath",{"id":356,"sortIndex":19,"researcher":18,"roles":357,"affiliations":358,"properties":364},"1cbd639d-48bb-414a-919a-09ab23ffcae6",[118],[359],{"id":18,"sortIndex":19,"affiliation":360,"properties":18},{"id":332,"createTime":333,"updateTime":334,"relativeEntities":361,"slug":336,"properties":362,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":363},{"VI":339},{"title":365},{"VI":366},"Mark C. Hanson",{"id":368,"sortIndex":133,"researcher":18,"roles":369,"affiliations":370,"properties":376},"4322d355-4ecc-40ad-a90b-a9e90665c8aa",[118],[371],{"id":18,"sortIndex":19,"affiliation":372,"properties":18},{"id":332,"createTime":333,"updateTime":334,"relativeEntities":373,"slug":336,"properties":374,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":375},{"VI":339},{"title":377},{"VI":378},"R. Wayne Alexander",{"url":324,"publisher":380,"properties":402},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":381,"slug":10,"properties":382,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":385,"manageAffiliations":386,"indexDatabases":387,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":383,"title":384},{"VOID":13},{"EN":15},[],[],[388,395],{"id":74,"indexDatabase":389,"url":87,"indexYears":88,"academicFieldIds":394,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":390,"label":391,"description":392,"key":84,"publicationTags":393,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":396,"url":70,"indexYears":18,"academicFieldIds":401,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":397,"label":398,"description":399,"key":66,"publicationTags":400,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":403,"pages":405},{"VOID":404},"306",{"VOID":406},"69-74","1993-08-01",1993,{"id":410,"createTime":411,"updateTime":412,"relativeEntities":413,"slug":414,"properties":415,"entityType":109,"verifyStatus":110,"verifyTime":412,"verifyNote":111,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":422,"fullTextUrl":18,"authors":423,"publicationType":156,"publisherRelationship":439,"citationCount":18,"citationInfo":18,"publishDate":467,"publishYear":468,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"c89f551d-ca18-4822-a480-d650cd8ef904","2023-12-28T18:04:11.842+00:00","2025-01-29T23:58:34.119+00:00",[],"Renal-Osteodystrophy-Pathogenesis-and-Treatment",{"references":416,"title":418,"doi":420},{"VOID":417},"Sherrard, 1982, Calcium and phosphate disorders: Renal osteodystrophy, 57\nRasmussen, 1974, The Physiological and Cellular Basis of Metabolic Bone Disease, 41\nRaisz, 1977, Bone metabolism and calcium regulation, 1\nRitz, 1977, Bone histology in renal insufficiency, 197\nRasmussen, 1974, The Physiological and Cellular Basis of Metabolic Bone Disease, 11\nTeitelbaum, 1980, Pathological manifestations of osteomalacia and rickets, Clin Endocrinol Metab, 9, 43, 10.1016\u002FS0300-595X(80)80020-X\nPosner, 1973, Bone mineral on the molecular level, Fed Proc, 32, 1933\nMelsen, 1980, Trabecular bone mineralization lag time determined by tetracycline double-labeling in normal and certain pathological conditions, Acta Pathol Microbiol Scand [A], 88, 83\nFallon, 1982, The interpretation of fluorescent tetracycline markers in the diagnosis of metabolic bone diseases, Hum Pathol, 13, 416, 10.1016\u002FS0046-8177(82)80023-3\nDavid, 1977, Mineral and bone homeostasis in renal failure: Pathophysiology and management, 1\nParfitt, 1976, The actions of parathyroid hormone on bone: Relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone diseases, Metabolism, 25, 909, 10.1016\u002F0026-0495(76)90124-4\nNeer, 1979, Calcium and inorganic-phosphate homeostasis, 669\nBlum, 1974, Acute parathyroid hormone response: Sensitivity, relationship to hypocalcemia, and rapidity, Endocrinology, 95, 753, 10.1210\u002Fendo-95-3-753\nCoburn, 1980, Renal osteodystrophy, Kidney Int, 17, 677, 10.1038\u002Fki.1980.79\nByers, 1977, The diagnostic value of bone biopsies, 184\nMalluche, 1976, Bone histology in incipient and advanced renal failure, Kidney Int, 9, 355, 10.1038\u002Fki.1976.42\nHruska, 1978, The predictability of the histological features of uremic bone disease by non-invasive techniques, Metab Bone Dis Relat Res, 1, 39, 10.1016\u002F0221-8747(78)90035-8\nCoburn, 1981, Vitamin D, parathyroid hormone, and renal osteodystrophy, 2213\nHolick, 1978, The photo-biogenesis and metabolism of vitamin D, Fed Proc, 37, 2567\nBrickman, 1977, Actions of 1 alpha-hydroxyvitamin D3 and 1,25-di-hydroxyvitamin D3 on mineral metabolism in man, Am J Clin Nutr, 30, 1064, 10.1093\u002Fajcn\u002F30.7.1064\nHoltrop, 1981, 1,25-dihydroxy-cholecalciferol stimulates osteoclasts in rat bones in the absence of parathyroid hormone, Endocrinology, 108, 2293, 10.1210\u002Fendo-108-6-2293\nMaierhofer, 1983, Bone resorption stimulated by elevated serum l,25-(OH)2D-vitamin D concentrations in healthy man, Kidney Int, 24, 555, 10.1038\u002Fki.1983.193\nSlatopolsky, 1979, The pathogenesis of secondary hyperparathyroidism in early renal failure, 1209\nJuttmann, 1981, Serum concentrations of metabolites of vitamin D in patients with chronic renal failure. Consequences for the treatment with alpha-hydroxy-derivatives, Clin Endocrinol, 14, 225, 10.1111\u002Fj.1365-2265.1981.tb00191.x\nOffermann, 1974, Serum 25-hydroxycholecalciferol in uremia, Nephron, 13, 269, 10.1159\u002F000180403\nPierides, 1976, Barbiturate and anticonvulsant treatment in relation to osteomalacia with hemodialysis and renal transplantation, Br Med J, 1, 190, 10.1136\u002Fbmj.1.6003.190\nStern, 1980, Evidence for abnormal regulation of circulating l-alpha-25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism, J Clin Invest, 66, 852, 10.1172\u002FJCI109924\nHaussler, 1975, 1 alpha, 25-dihydroxyvitamin D3 in idiopathic hypoparathyroidism: Assay of circulating concentration and therapeutic effect of the sterol, Clinical Research, 23, 155A\nReiss, 1968, Experience with a radioimmunoassay of parathyroid hormone in human sera, Trans Assoc Am Physicians, 81, 104\nBikle, 1975, The ionic control of 1,25-dihydroxyvitamin D3 synthesis of isolated chick renal mitochondria. The role of calcium as influenced by inorganic phosphate and hydrogen ion, J Clin Invest, 55, 299, 10.1172\u002FJCI107933\nPortale, 1982, Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency, Kidney Int, 21, 627, 10.1038\u002Fki.1982.70\nPortale, 1982, Effect of dietary phosphorus on plasma 1,25-(OH)2D in children with moderate renal insufficiency, Kidney Int, 21, 139, 10.1038\u002Fki.1982.70\nKawashima, 1981, Localization of 25-hydroxy-vitamin D3 1 alpha-hydroxylase and 24-hydroxylase along the rat nephron, Proc Natl Acad Sci USA, 78, 1199, 10.1073\u002Fpnas.78.2.1199\nBrewer, 1977, Maleic acid-induced impaired conversion of 25(OH)D3 to 1,25-(OH)2D3: Implications for Fanconi’s syndrome, Kidney Int, 12, 244, 10.1038\u002Fki.1977.109\nChesney, 1982, Circulating vitamin D metabolite concentrations in childhood renal diseases, Kidney Int, 21, 65, 10.1038\u002Fki.1982.9\nCoburn, 1969, The physicochemical state and renal handling of divalent ions in chronic renal failure, Arch Intern Med, 124, 302, 10.1001\u002Farchinte.1969.00300190042007\nStanbury, 1962, Metabolic studies of renal osteodystrophy. I. Calcium, phosphorus, and nitrogen metabolism in rickets, osteomalacia, and hyperparathyroidism complicating chronic uremia and the osteomalacia of the adult Fanconi syndrome, Medicine, 41, 1, 10.1097\u002F00005792-196202000-00001\nLlach, 1975, Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism, J Clin Endocrinol Metab, 41, 339, 10.1210\u002Fjcem-41-2-339\nGarabedian, 1976, Response of intestinal calcium transport and bone calcium mobilization to 1,25-dihydroxyvitamin D3 in thyroparathyroidectomized rats, Endocrinology, 94, 1022, 10.1210\u002Fendo-94-4-1022\nReiss, 1970, The role of phosphate in the secretion of parathyroid hormone in man, J Clin Invest, 49, 2146, 10.1172\u002FJCI106432\nGoldsmith, 1975, Effects of calcium and phosphorus on patients maintained on dialysis, Kidney Int, 7, S118\nParker, 1980, Magnesium and calcium mass transfer during continuous ambulatory peritoneal dialysis, Trans Am Soc Artif Intern Organs, 26, 194\nArnaud, 1973, Hyperparathyroidism and renal failure, Kidney Int, 4, 89, 10.1038\u002Fki.1973.87\nSlatopolsky, 1971, On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog, J Clin Invest, 50, 492, 10.1172\u002FJCI106517\nBricker, 1972, On the pathogenesis of the uremic state. An exposition of the “trade-off hypothesis.”, N Engl J Med, 286, 1093, 10.1056\u002FNEJM197205182862009\nSlatopolsky, 1973, The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease, Kidney Int, 4, 141, 10.1038\u002Fki.1973.92\nLlach, 1977, Secondary hyperparathyroidism in early renal failure: Role of phosphate retention, Kidney Int, 12, 459\nSlatopolsky, 1983, Marked suppression of secondary hyperparathyroidism by intravenous 1,25-(OH)2D3 in uremic patients, Kidney Int, 23, 162\nRutherford, 1977, Phosphate control and 25-hydroxy-cholecalciferol administration in preventing experimental renal osteodystrophy in the dog, J Clin Invest, 60, 332, 10.1172\u002FJCI108781\nBordier, 1973, Fournier A, deWardener HE: Lack of histological evidence of vitamin D abnormality in the bones of anephric patients, Clin Sci, 44, 33, 10.1042\u002Fcs0440033\nKanis, 1977, Vitamin D, osteomalacia and chronic renal failure, 671\nAlbright, 1948, 116\nLemann, 1972, Role of diet, gastrointestinal tract and bone in acid-base homeostasis, Kidney Int, 1, 275, 10.1038\u002Fki.1972.40\nLitzow, 1967, The effect of treatment of acidosis on calcium balance in patients with chronic azotemic renal disease, J Clin Invest, 46, 280, 10.1172\u002FJCI105530\nGriffith, 1965, Heparin osteoporosis, JAMA, 193, 91, 10.1001\u002Fjama.1965.03090020005001\nJaffe, 1965, Multiple fractures associated with long-term sodium heparin therapy, JAMA, 193, 158, 10.1001\u002Fjama.1965.03090020072024\nBaker, 1974, Iatrogenic osteomalacia and myopathy due to phosphate depletion, Br Med J, 3, 150, 10.1136\u002Fbmj.3.5924.150\nAbrams, 1974, Antacid induction of phosphate depletion syndrome in renal failure, West J Med, 120, 157\nMahony, 1976, Hypophosphatémie osteomalacia in patients receiving hemodialysis, Br Med J, 2, 142, 10.1136\u002Fbmj.2.6028.142\nPlatts, 1977, Composition of the domestic water supply and the incidence of fractures and encelopathy in patients on home dialysis, Br Med J, 2, 657, 10.1136\u002Fbmj.2.6088.657\nKaehny, 1977, Aluminum transfer during hemodialysis, Kidney Int, 12, 361, 10.1038\u002Fki.1977.123\nPierides, 1980, Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness, Kidney Int, 18, 10.1038\u002Fki.1980.117\nWard, 1978, Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminum, Lancet, 1, 841, 10.1016\u002FS0140-6736(78)90191-5\nParkinson, 1979, Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey, Lancet, 1, 406, 10.1016\u002FS0140-6736(79)90883-3\nComty, 1978, Pretreatment and preparation of city water for hemodialysis, 155\nOtt, 1982, The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy, N Engl J Med, 307, 709, 10.1056\u002FNEJM198209163071202\nCournot-Witmer, 1981, Aluminum localization in bone from hemodialyzed patients: Relationship to bone matrix mineralization, Kidney Int, 20, 375, 10.1038\u002Fki.1981.149\nEllis, 1979, Bone aluminum in hemodialyzed patients and in rats injected with aluminum chloride: Relationship to impaired bone mineralization, J Clin Pathol, 32, 832, 10.1136\u002Fjcp.32.8.832\nRobertson, 1983, Animal model of aluminum-induced osteomalacia: Role of chronic renal failure, Kidney Int, 23, 327, 10.1038\u002Fki.1983.23\nGoodman, 1982\nOtt, 1983, Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition, Ann Intern Med, 98, 910, 10.7326\u002F0003-4819-98-6-910\nHodsman, 1981, Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism, Ann Intern Med, 94, 629, 10.7326\u002F0003-4819-94-5-629\nBoyce, 1982, Hypercalcemic osteomalacia due to aluminum toxicity, Lancet, 2, 1009, 10.1016\u002FS0140-6736(82)90049-6\nSherrard, 1982, The use of 24,25(OH)2D in the refractory osteomalacia form of renal osteodystrophy, 169\nRodan, 1981, Role of osteoblasts in hormonal control of bone resorption—A hypothesis, Caleif Tissue Int, 33, 349, 10.1007\u002FBF02409454\nFelsenfeld, 1982, Osteomalacia after parathyroidectomy in patients with uremia, Ann Intern Med, 96, 34, 10.7326\u002F0003-4819-96-1-34\nTeitelbaum, 1980, Do parathyroid hormone and 1,25-dihydroxyvitamin D modulate bone formation in uremia?, J Clin Endocrinol Metab, 51, 247, 10.1210\u002Fjcem-51-2-247\nHodsman, 1982, Bone aluminum and histomorphometric features of renal osteodystrophy, J Clin Endocrinol Metab, 54, 539, 10.1210\u002Fjcem-54-3-539\nMorrissey, 1982, Suppression of parathyroid hormone release by aluminum, Kidney Int, 21, 138\nHealy, 1980, Effects of long-term therapy with calcitriol in patients with moderate renal failure, Arch Intern Med, 140, 1030, 10.1001\u002Farchinte.1980.00330190042017\nChan, 1981, Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure, Pediatrics, 68, 559, 10.1542\u002Fpeds.68.4.559\nTeitelbaum, 1981, Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease, Ann Intern Med, 94, 404, 10.7326\u002F0003-4819-94-3-404\nChristiansen, 1978, Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol, Lancet, 2, 700, 10.1016\u002FS0140-6736(78)92702-2\nTougaard, 1976, Controlled trial of 1 alpha-hydroxycholecalciferol in chronic renal failure, Lancet, 1, 1044, 10.1016\u002FS0140-6736(76)92220-0\nMassry, 1979, Is calcitriol harmful to renal function?, JAMA, 242, 1875, 10.1001\u002Fjama.242.17.1875\nCurtis, 1970, deWardener H, Gower P, Eastwood JB: The use of calcium carbonate and calcium phosphate without vitamin D in the management of renal osteodystrophy, Proc Eur Dial Transplant Assoc, 7, 141\nMeyrier, 1973, The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis, Kidney Int, 4, 146, 10.1038\u002Fki.1973.93\nSherrard, 1980, Skeletal response to treatment with 1,25-dihydroxy-vitamin D in renal failure, Contrib Nephrol, 18, 92, 10.1159\u002F000403276\nKaehny, 1977, Gastrointestinal absorption of aluminum from aluminum-containing antacids, N Engl J Med, 296, 1389, 10.1056\u002FNEJM197706162962407\nMoriniere, 1983, Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic hemodialysis: Disappearance of hyperaluminemia and equal control of hyperparathyroidism, Proc Eur Dial Transplant Assoc, 19, 784\nMarkoff, 1969, Calcium carbonate therapy in uremia, Arch Intern Med, 123, 15, 10.1001\u002Farchinte.1969.00300110017003\nHodsman, 1983, Preliminary trials with 24,25-dihydroxyvitamin D3 in dialysis osteomalacia, Am J Med, 74, 407, 10.1016\u002F0002-9343(83)90959-2\nOtt, 1983, Vitamin D therapy in aluminum-related osteomalacia, Kidney Int, 23, 107\nMilliner, 1984, Use of deferoxamine infusion test in diagnosis of aluminum-related osteodystrophy, Ann Intern Med, 101, 775, 10.7326\u002F0003-4819-101-6-775\nMalluche, 1984, The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure, N Engl J Med, 311, 140, 10.1056\u002FNEJM198407193110302\nNebeker, 1984\nGokal, 1983, Histological renal osteodystrophy, and 25-hydroxycholecalciferol and aluminum levels in patients on continuous ambulatory peritoneal dialysis, Kidney Int, 23, 15, 10.1038\u002Fki.1983.4\nGokal, 1981, Improvement in secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis, 461\nDelmez, 1982, Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis, Kidney Int, 21, 862, 10.1038\u002Fki.1982.110",{"EN":419},"Renal Osteodystrophy—Pathogenesis and Treatment",{"VOID":421},"10.1097\u002F00000441-198512000-00003","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0002962915370518",[424],{"id":425,"sortIndex":19,"researcher":18,"roles":426,"affiliations":427,"properties":436},"7664d1fa-06f7-4368-866c-7eb78e44d91a",[118],[428],{"id":18,"sortIndex":19,"affiliation":429,"properties":18},{"id":430,"createTime":431,"updateTime":431,"relativeEntities":432,"slug":18,"properties":433,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"98385f3c-22a5-4df6-bb0d-3f12c589c77e","2023-12-28T18:04:11.861+00:00",[],{"title":434},{"VI":435},"Departments of Medicine, Divisions of Nephrology, The University of Texas Health Science Center at San Antonio and Brooke Army Medical Center, Fort Sam Houston, Texas",{"title":437},{"VI":438},"Maj. Howard M. Cushner",{"url":422,"publisher":440,"properties":462},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":441,"slug":10,"properties":442,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":445,"manageAffiliations":446,"indexDatabases":447,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":443,"title":444},{"VOID":13},{"EN":15},[],[],[448,455],{"id":74,"indexDatabase":449,"url":87,"indexYears":88,"academicFieldIds":454,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":450,"label":451,"description":452,"key":84,"publicationTags":453,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":456,"url":70,"indexYears":18,"academicFieldIds":461,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":457,"label":458,"description":459,"key":66,"publicationTags":460,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":463,"pages":465},{"VOID":464},"290",{"VOID":466},"234-245","1985-12-01",1985,{"id":470,"createTime":471,"updateTime":471,"relativeEntities":472,"slug":473,"properties":474,"entityType":109,"verifyStatus":17,"verifyTime":471,"verifyNote":485,"syncStatus":17,"languages":486,"translateLanguages":18,"viewCount":19,"primaryUrl":488,"fullTextUrl":18,"authors":489,"publicationType":156,"publisherRelationship":499,"citationCount":529,"citationInfo":530,"publishDate":532,"publishYear":533,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":534,"isForceReanalyzing":187},"5fdec501-1b90-4e49-a8b0-7f97d9460cbe","2024-10-01T23:56:01.456+00:00",[],"THROMBOSIS-OF-THE-CORONARY-ARTERIES-WITH-INFARCTION-OF-THE-HEART",{"mag":475,"keywords":477,"openalex":478,"abstract":480,"title":481,"doi":483},{"VOID":476},"2068996483",{},{"VOID":479},"W2068996483",{},{"EN":482},"THROMBOSIS OF THE CORONARY ARTERIES, WITH INFARCTION OF THE HEART",{"VOID":484},"10.1097\u002F00000441-192302000-00008","Author affiliation is blank",[487],"EN","http:\u002F\u002Fcontent.wkhealth.com\u002Flinkback\u002Fopenurl?sid=WKPTLP:landingpage&an=00000441-192302000-00008",[490],{"id":491,"sortIndex":19,"researcher":18,"roles":492,"affiliations":493,"properties":494},"afea1e6d-e9b5-4edd-8495-55ce3d26a5da",[],[],{"openalex":495,"title":497},{"VOID":496},"A5073753198",{"EN":498},"Joseph T. Wearn",{"url":18,"publisher":500,"properties":522},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":501,"slug":10,"properties":502,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":505,"manageAffiliations":506,"indexDatabases":507,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":503,"title":504},{"VOID":13},{"EN":15},[],[],[508,515],{"id":74,"indexDatabase":509,"url":87,"indexYears":88,"academicFieldIds":514,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":510,"label":511,"description":512,"key":84,"publicationTags":513,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":516,"url":70,"indexYears":18,"academicFieldIds":521,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":517,"label":518,"description":519,"key":66,"publicationTags":520,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":523,"pages":525,"issue":527},{"VOID":524},"165",{"VOID":526},"250-275",{"VOID":528},"2",95,{"total":529,"publishYear":18,"statisticByYear":531},{"2013":116,"2015":133,"2016":116,"2017":248,"2018":116,"2019":116,"2020":116,"2022":116,"2023":116},"1923-02-01",1923,[],{"id":536,"createTime":537,"updateTime":538,"relativeEntities":539,"slug":540,"properties":541,"entityType":109,"verifyStatus":17,"verifyTime":538,"verifyNote":546,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":547,"fullTextUrl":18,"authors":548,"publicationType":156,"publisherRelationship":549,"citationCount":18,"citationInfo":18,"publishDate":579,"publishYear":580,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"72396fd1-8305-4b3e-81be-33be6a928063","2023-12-09T17:25:12.607+00:00","2024-09-22T23:55:46.155+00:00",[],"Measles-Encephalitis-and-Acute-Pancreatitis-in-a-Young-Adult",{"title":542,"doi":544},{"EN":543},"Measles Encephalitis and Acute Pancreatitis in a Young Adult",{"VOID":545},"10.1097\u002F00000441-200405000-00034","Author title is blank","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0002962915340878",[],{"url":547,"publisher":550,"properties":572},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":551,"slug":10,"properties":552,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":555,"manageAffiliations":556,"indexDatabases":557,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":553,"title":554},{"VOID":13},{"EN":15},[],[],[558,565],{"id":74,"indexDatabase":559,"url":87,"indexYears":88,"academicFieldIds":564,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":560,"label":561,"description":562,"key":84,"publicationTags":563,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":566,"url":70,"indexYears":18,"academicFieldIds":571,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":567,"label":568,"description":569,"key":66,"publicationTags":570,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":573,"pages":575,"issue":577},{"VOID":574},"327",{"VOID":576},"299-303",{"VOID":578},"5","2004-05-01",2004,{"id":582,"createTime":583,"updateTime":584,"relativeEntities":585,"slug":586,"properties":587,"entityType":109,"verifyStatus":110,"verifyTime":584,"verifyNote":111,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":594,"fullTextUrl":18,"authors":595,"publicationType":156,"publisherRelationship":613,"citationCount":18,"citationInfo":18,"publishDate":641,"publishYear":642,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"1900caf5-401b-462f-a921-f1b1b705b7af","2023-12-07T14:54:59.819+00:00","2025-02-06T23:54:54.871+00:00",[],"Ocular-Complications-of-Systemic-Medications",{"references":588,"title":590,"doi":592},{"VOID":589},"Chang, 2005, Intraoperative floppy iris syndrome associated with tamsulosin, J Cataract Refract Surg, 31, 664, 10.1016\u002Fj.jcrs.2005.02.027\nHerd, 2007, Intraoperative floppy-iris syndrome with doxazosin, J Cataract Refract Surg, 33, 562, 10.1016\u002Fj.jcrs.2006.11.019\nYeu, 2007, Saw palmetto and intraoperative floppy-iris syndrome, J Cataract Refract Surg, 33, 927, 10.1016\u002Fj.jcrs.2006.12.032\nChang, 2007, A prospective multi-center evaluation of cataract surgery in patients taking tamsulosin (Flomax), Ophthalmology, 114, 957, 10.1016\u002Fj.ophtha.2007.01.011\nBlouin, 2007, Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptor: comparison of tamsulosin and alfuzosin, J Cataract Refract Surg, 33, 1227, 10.1016\u002Fj.jcrs.2007.03.032\nFriedman, 2009, Tamsulosin and the intraoperative floppy iris syndrome, JAMA, 301, 2044, 10.1001\u002Fjama.2009.704\nFlach, 2009, Intraoperative floppy iris syndrome: pathophysiology, prevention, and treatment, Trans Am Ophthalmol Soc, 107, 234\nLaties, 1999, Ocular safety of Viagra, (sildenafil citrate), Trans Am Ophthalmol Soc, 97, 115\nBorillo, 1998, Dangers of Viagra use in pilots: AMEs should become familiar with the detrimental side-effects of sildenafil, Federal Air Surgeons Med Bull Fall\nPomeranz, 2002, Sildenafil-associated nonarteritic anterior ischemic optic neuropathy, Ophthalmology, 109, 584, 10.1016\u002FS0161-6420(01)00976-9\nFraunfelder, 2006, Nonarteritic anterior ischemic optic neuropathy and sildenafil, Arch Ophthalmol, 124, 733, 10.1001\u002Farchopht.124.5.733\nFraunfelder, 2004, Topiramate-associated acute, bilateral, secondary angle-closure glaucoma, Ophthalmology, 111, 109, 10.1016\u002Fj.ophtha.2003.04.004\nBanta, 2001, Presumed topiramate-induced bilateral acute angle-closure glaucoma, Am J Ophthalmol, 132, 112, 10.1016\u002FS0002-9394(01)01013-3\nRhee, 2001, Bilateral angle-closure glaucoma and ciliary body swelling from topiramate, Arch Ophthalmol, 119, 1721\nFraunfelder, 2004, Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects, Ophthalmology, 111, 1275, 10.1016\u002Fj.ophtha.2003.12.052\nMustafa, 1995, Diversity of GABA receptors in the vertebrate outer retina, Trends Neurosci, 18, 118, 10.1016\u002F0166-2236(95)93886-3\nWillmore, 2009, Vigabatrin: 2008 update, Epilepsia, 50, 163, 10.1111\u002Fj.1528-1167.2008.01988.x\nKrauss, 2009, Evaluating risk for vigabatrin treatment, Epilepsy Currents, 9, 125, 10.1111\u002Fj.1535-7511.2009.01315.x\nBuncic, 2004, Characteristic retinal atrophy with secondary “inverse” optic atrophy identifies vigabatrin toxicity in children, Ophthalmology, 111, 1935, 10.1016\u002Fj.ophtha.2004.03.036\nImperia, 1989, Ocular complications of systemic cancer chemotherapy, Surv Ophthalmol, 34, 209, 10.1016\u002F0039-6257(89)90105-7\nBurns, 1992, Ocular toxicities of chemotherapy, Semin Oncol, 19, 492\nAl-Tweigeri, 1996, Ocular toxicity and cancer chemotherapy. A review, Cancer, 78, 1359, 10.1002\u002F(SICI)1097-0142(19961001)78:7\u003C1359::AID-CNCR1>3.0.CO;2-G\nSchmi, 2006, Update on ocular complications of systemic cancer chemotherapy, Surv Ophthalmol, 51, 19, 10.1016\u002Fj.survophthal.2005.11.001\nKapp, 1985, Supraophthalmic carotid infusion for recurrent glioma, J Neurooncol, 3, 5, 10.1007\u002FBF00165165\nBrink, 1995, Punctal and canalicular stenosis associated with systemic fluorouracil therapy, Doc Ophthalmol, 90, 1, 10.1007\u002FBF01203288\nLass, 1982, Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine, Am J Ophthalmol, 94, 617, 10.1016\u002F0002-9394(82)90006-X\nAlbert, 1967, Ocular complications of vincristine therapy, Arch Ophthalmol, 78, 709, 10.1001\u002Farchopht.1967.00980030711004\nSeidman, 1994, Photopsia during 3-hour paclitaxel administration at doses > or = 250mg\u002Fm2, J Clin Oncol, 12, 1741, 10.1200\u002FJCO.1994.12.8.1741\nEsmaeli, 2001, Canalicular stenosis secondary to docetaxel (Taxotere). A newly recognized side effect, Ophthalmology, 108, 994, 10.1016\u002FS0161-6420(00)00640-0\nTeitelbaum, 2003, Cystic maculopathy with normal capillary permeability secondary to docetaxel, Optom Vis Sci, 80, 227, 10.1097\u002F00006324-200304000-00004\nJoshi, 2007, Paclitaxel maculopathy, Arch Ophthalmol, 125, 709, 10.1001\u002Farchopht.125.5.709\nKawano, 1996, Retinal complications during interferon therapy for chronic hepatitis C, Am J Gastroenterol, 91, 309\nPurvin, 1995, Anterior ischemic optic neuropathy secondary to interferon alfa, Arch Ophthalmol, 113, 1041, 10.1001\u002Farchopht.1995.01100080093034\nTang, 1995, Interferon: friend or foe?, Arch Ophthalmol, 113, 987, 10.1001\u002Farchopht.1995.01100080037026\nEsmaeli, 2001, Interferon-induced retinopathy in asymptomatic cancer patients, Ophthalmology, 108, 858, 10.1016\u002FS0161-6420(01)00546-2\nPaganini-Hill, 2000, Eye problems in breast cancer patients treated with tamoxifen, Breast Cancer Res Treat, 60, 167, 10.1023\u002FA:1006342300291\nPavlidis, 1992, Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity: a prospective study of 63 patients, Cancer, 69, 2961, 10.1002\u002F1097-0142(19920615)69:12\u003C2961::AID-CNCR2820691215>3.0.CO;2-W\nVogel, 2006, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial, JAMA, 295, 2727, 10.1001\u002Fjama.295.23.joc60074\nKwok, 1997, Ocular-hypertensive response to topical steroids in children, Ophthalmology, 104, 2112, 10.1016\u002FS0161-6420(97)30052-9\nMeredith, 1978, Progressive chorioretinopathy after receiving thioridazine, Arch Ophthalmol, 96, 1172, 10.1001\u002Farchopht.1978.03910060006002\nHagopian, 1966, Five cases of pigmentary retinopathy associated with thioridazine administration, Am J Psychiatry, 123, 97, 10.1176\u002Fajp.123.1.97\nMäntyjärvi, 1998, Ocular side effects of amiodarone, Surv Ophthalmol, 42, 360, 10.1016\u002FS0039-6257(97)00118-5\nYounge, 2007, Amiodarone and ischemic optic neuropathy, J Neuroophthalmol, 27, 85, 10.1097\u002FWNO.0b013e3180334a06\nNagra, 2003, Amiodarone induced optic neuropathy, Br J Ophthalmol, 87, 420, 10.1136\u002Fbjo.87.4.420\nPurvin, 2006, Optic neuropathy in patients using amiodarone, Arch Ophthalmol, 124, 696, 10.1001\u002Farchopht.124.5.696\nBlomquist, 2000, Screening for hydroxychloroquine retinopathy, Comp Ophthalmol Update, 1, 245\nMarmor, 2002, Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. A report by the American Academy of Ophthalmology, Ophthalmology, 109, 1377, 10.1016\u002FS0161-6420(02)01168-5\nAmerican Academy of Ophthalmology, 2005\nSadun, 2008, Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year, J Neuroophthalmol, 28, 1, 10.1097\u002FWNO.0b013e31818f138f\nKline, 2005\nLaties, 1991, Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results II. Assessment of the human lens after 48 weeks of treatment with lovastatin, Am J Cardiology, 67, 447, 10.1016\u002F0002-9149(91)90002-3\nFraunfelder, 2008, Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use, Ophthalmology, 115, 2282, 10.1016\u002Fj.ophtha.2008.08.006\nMillay, 1988, Niacin maculopathy, Ophthalmology, 95, 930, 10.1016\u002FS0161-6420(88)33073-3\nHughes, 1990, Trazadone-induced palinopsia, Arch Ophthamol, 108, 399, 10.1001\u002Farchopht.1990.01070050097040\nPurvin, 1995, Visual disturbance secondary to clomiphene citrate, Arch Ophthalmol, 113, 482, 10.1001\u002Farchopht.1995.01100040102034\nFraunfelder, 2009, Diplopia and fluoroquinolones, Ophthalmology, 116, 1814, 10.1016\u002Fj.ophtha.2009.06.027\nJeng, 2008, Amantadine-associated corneal edema. Potentially irreversible even after cessation of the medication, Ophthalmology, 115, 1540, 10.1016\u002Fj.ophtha.2008.03.011\nAmbrosius, 2010, Lack of association between thiazolidinediones and macular edema in type 2 diabetics. The ACCORD Eye Substudy, Arch Ophthalmol, 128, 312, 10.1001\u002Farchophthalmol.2009.310\nTasman, 2007, AJO History of Ophthalmology Series. Bilberry and the Royal Air Force, Am J Ophthalmol, 144, 556, 10.1016\u002FS0002-9394(07)00826-4\nSchey, 2000, Photooxidation of lens alpha-crystallin by hypericin (active ingredient in St. John’s Wort), Photochem Photobiol, 72, 200, 10.1562\u002F0031-8655(2000)072\u003C0200:POLCBH>2.0.CO;2\nBooth, 2009, The association between self-reported cataracts and St. John’s Wort, Curr Eye Res, 34, 863, 10.3109\u002F02713680903144692\nFraunfelder, 2004, Ocular side effects from herbal medicines and nutritional supplements, Am J Ophthalmol, 138, 639, 10.1016\u002Fj.ajo.2004.04.072",{"EN":591},"Ocular Complications of Systemic Medications",{"VOID":593},"10.1097\u002Fmaj.0b013e3181f06b21","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0002962915312465",[596],{"id":597,"sortIndex":19,"researcher":18,"roles":598,"affiliations":599,"properties":610},"39035a6c-0528-4337-92fe-dc2f855c54a8",[118],[600],{"id":18,"sortIndex":19,"affiliation":601,"properties":18},{"id":602,"createTime":603,"updateTime":604,"relativeEntities":605,"slug":606,"properties":607,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"0786773a-741b-40e9-a064-6e654b764346","2023-12-11T18:48:53.963+00:00","2025-06-11T20:33:46.825+00:00",[],"Department-of-Ophthalmology-University-of-Texas-Southwestern-Medical-Center-Dallas-Texas",{"title":608},{"VI":609},"Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas",{"title":611},{"VI":612},"Preston H. Blomquist",{"url":594,"publisher":614,"properties":636},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":615,"slug":10,"properties":616,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":619,"manageAffiliations":620,"indexDatabases":621,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":617,"title":618},{"VOID":13},{"EN":15},[],[],[622,629],{"id":74,"indexDatabase":623,"url":87,"indexYears":88,"academicFieldIds":628,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":624,"label":625,"description":626,"key":84,"publicationTags":627,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":630,"url":70,"indexYears":18,"academicFieldIds":635,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":631,"label":632,"description":633,"key":66,"publicationTags":634,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":637,"pages":639},{"VOID":638},"342",{"VOID":640},"62-69","2011-07-01",2011,{"id":644,"createTime":645,"updateTime":645,"relativeEntities":646,"slug":18,"properties":647,"entityType":109,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":654,"fullTextUrl":18,"authors":655,"publicationType":156,"publisherRelationship":719,"citationCount":18,"citationInfo":18,"publishDate":747,"publishYear":748,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"a2e72c71-5299-42bd-b797-dc5f54f6160a","2024-01-12T23:54:33.100+00:00",[],{"references":648,"title":650,"doi":652},{"VOID":649},"McGary, 1980, In vitro simulations of peritoneal dialysis, J Lab Clin Med, 96, 148\nShinaberger, 1965, Increasing efficiency of peritoneal dialysis: Experience with peritoneal-extracorporeal recirculation dialysis, ASAIO Trans, 11, 376, 10.1097\u002F00002480-196504000-00015\nMiller, 1966, Automated peritoneal dialysis: Analysis of several methods of peritoneal dialysis, ASAIO Trans, 12, 98\nPenzotti, 1968, Acceleration of peritoneal dialysis by surface active agents, JPharm Sci, 57, 1192, 10.1002\u002Fjps.2600570722\nCrocker, 1967, Rapid determination of urea nitrogen on serum or plasma without deproteinization, American Journal Medical Technology, 33, 361\nWalser, 1955, The renal clearance of alkali- stable inulin, J Clin Invest, 34, 1520, 10.1172\u002FJCI103204\nBrown, 1977, Chemical measurements of inulin concentrations in peritoneal dialysis solution, Clin Chim Acta, 76, 103, 10.1016\u002F0009-8981(77)90123-1\nHenry, 1956, Turbidometric determination of proteins with sulfosalicylic and trichloroacetic acids, Proc Soc Exp Biol Med, 92, 748, 10.3181\u002F00379727-92-22601\nPopovich, 1985, Transport kinetics, 120\nRanderson, 1980, Mass transfer properties of the human peritoneum, ASAIO Journal, 3, 140\nRubin, 1985, A double blind trial of dipyridamole in CAPD, Am J Kidney Dis, 5, 262, 10.1016\u002FS0272-6386(85)80119-0\nGarred, 1983, A simple kinetic model for assessing mass transfer coefficients and microvascular physiology, ASAIO Journal, 6, 131\nSnedecor, 1967\nMiller, 1979, Comparison of the effects of altered peritoneal dialysis solutions on the microcirculation of the rat and on peritoneal clearances in man, Kidney Int, 15, 630, 10.1038\u002Fki.1979.83\nRubin, 1979, Follow-up of hourly peritoneal clearances with and without nitroprusside augmentation in patients undergoing CAPD, Kidney Int, 16, 619, 10.1038\u002Fki.1979.172\nBrown, 1978, Effect of hypertonic dialysate and vasodilators on peritoneal clearances in the rat, Kidney Int, 13, 271, 10.1038\u002Fki.1978.40\nRasio, 1974, Metabolic control of permeability in isolated mesentery, Am J Physiol, 226, 962, 10.1152\u002Fajplegacy.1974.226.4.962\nDainty, 1963, Water relations of plant cells, Vol 1, 279\nHays, 1970, Do large pores exist in epithelial cell membranes?, 509\nDainty, 1966, Unstirred layers in frog skin, J Physiol, 182, 66, 10.1113\u002Fjphysiol.1966.sp007809",{"EN":651},"Enhancement of Peritoneal Transport in Rats by Disrupting Stagnant Fluid Films",{"VOID":653},"10.1097\u002F00000441-198802000-00004","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0002962915366179",[656,671,683,695,707],{"id":657,"sortIndex":19,"researcher":18,"roles":658,"affiliations":659,"properties":668},"c2b90f27-95cb-4511-92de-d223c5b42d9a",[118],[660],{"id":18,"sortIndex":19,"affiliation":661,"properties":18},{"id":662,"createTime":663,"updateTime":663,"relativeEntities":664,"slug":18,"properties":665,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"41d93fe2-2c24-478b-9394-3a51440e49a4","2024-01-12T23:54:33.151+00:00",[],{"title":666},{"VI":667},"Department of Medicine, The University of Mississippi Medical Center, Jackson, Mississippi.",{"title":669},{"VI":670},"Jack Rubin",{"id":672,"sortIndex":133,"researcher":18,"roles":673,"affiliations":674,"properties":680},"426d12cb-a488-4c8c-bfb8-e5eb88ce18de",[118],[675],{"id":18,"sortIndex":19,"affiliation":676,"properties":18},{"id":662,"createTime":663,"updateTime":663,"relativeEntities":677,"slug":18,"properties":678,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":679},{"VI":667},{"title":681},{"VI":682},"Angela Planch",{"id":684,"sortIndex":248,"researcher":18,"roles":685,"affiliations":686,"properties":692},"35362ed3-b34c-4624-b06a-39d5049dff80",[118],[687],{"id":18,"sortIndex":19,"affiliation":688,"properties":18},{"id":662,"createTime":663,"updateTime":663,"relativeEntities":689,"slug":18,"properties":690,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":691},{"VI":667},{"title":693},{"VI":694},"Virginia Lockard",{"id":696,"sortIndex":116,"researcher":18,"roles":697,"affiliations":698,"properties":704},"41a4584c-b9e5-41d7-bc0c-d3f42cb4af4a",[118],[699],{"id":18,"sortIndex":19,"affiliation":700,"properties":18},{"id":662,"createTime":663,"updateTime":663,"relativeEntities":701,"slug":18,"properties":702,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":703},{"VI":667},{"title":705},{"VI":706},"Quintus Jones",{"id":708,"sortIndex":218,"researcher":18,"roles":709,"affiliations":710,"properties":716},"da7d4880-d37f-4ea3-b2c7-2f49e97d9c0e",[118],[711],{"id":18,"sortIndex":19,"affiliation":712,"properties":18},{"id":662,"createTime":663,"updateTime":663,"relativeEntities":713,"slug":18,"properties":714,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":715},{"VI":667},{"title":717},{"VI":718},"John Bower",{"url":654,"publisher":720,"properties":742},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":721,"slug":10,"properties":722,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":725,"manageAffiliations":726,"indexDatabases":727,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":723,"title":724},{"VOID":13},{"EN":15},[],[],[728,735],{"id":74,"indexDatabase":729,"url":87,"indexYears":88,"academicFieldIds":734,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":730,"label":731,"description":732,"key":84,"publicationTags":733,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":736,"url":70,"indexYears":18,"academicFieldIds":741,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":737,"label":738,"description":739,"key":66,"publicationTags":740,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":743,"pages":745},{"VOID":744},"295",{"VOID":746},"108-113","1988-02-01",1988,{"id":750,"createTime":751,"updateTime":752,"relativeEntities":753,"slug":754,"properties":755,"entityType":109,"verifyStatus":17,"verifyTime":752,"verifyNote":485,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":762,"fullTextUrl":18,"authors":763,"publicationType":156,"publisherRelationship":771,"citationCount":18,"citationInfo":18,"publishDate":799,"publishYear":800,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"eb5d95eb-2272-4458-8e34-6a94d9b37a61","2024-01-14T12:55:22.828+00:00","2024-12-23T23:54:21.309+00:00",[],"Curcumin-Inhibits-Apoptosis-and-Brain-Edema-Induced-by-Hypoxia-Hypercapnia-Brain-Damage-in-Rat-Models",{"references":756,"title":758,"doi":760},{"VOID":757},"Bein, 2005, Pumpless extracorporeal lung assist (pECLA) in patients with acute respiratory distress syndrome and severe brain injury, J Trauma, 58, 1294, 10.1097\u002F01.TA.0000173275.06947.5C\nMurakami, 1999, Cold injury in mice: a model to study mechanisms of brain edema and neuronal apoptosis, Prog Neurobiol, 57, 289, 10.1016\u002FS0301-0082(98)00047-1\nGeddes, 2003, Dural haemorrhage in nontraumatic infant deaths: does it explain the bleeding in “shaken baby syndrome”?, Neuropathol Appl Neurobiol, 29, 14, 10.1046\u002Fj.1365-2990.2003.00434.x\nAdditives JFWECoF, 2004\nChirangini, 2004, Sulfur free radical reactivity with curcumin as reference for evaluating antioxidant properties of medicinal Zingiberales, J Environ Pathol Toxicol Oncol, 23, 8, 10.1615\u002FJEnvPathToxOncol.v23.i3.60\nTung, 2008, Anti-inflammation activities of essential oil and its constituents from indigenous cinnamon (\u003C i> Cinnamomum osmophloeum\u003C\u002Fi>) twigs, Bioresour Technol, 99, 3908, 10.1016\u002Fj.biortech.2007.07.050\nYu, 2012, Effects of curcumin on levels of nitric oxide synthase and AQP-4 in a rat model of hypoxia–ischemic brain damage, Brain Res, 1475, 88, 10.1016\u002Fj.brainres.2012.07.055\nDoyle, 2008, Mechanisms of ischemic brain damage, Neuropharmacology, 55, 310, 10.1016\u002Fj.neuropharm.2008.01.005\nBeer, 2000, Expression of Fas and Fas ligand after experimental traumatic brain injury in the rat, J Cereb Blood Flow Metab, 20, 669, 10.1097\u002F00004647-200004000-00004\nTaga, 2002, αv-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin, Int J Cancer, 98, 690, 10.1002\u002Fijc.10265\nCole, 2007, Neuroprotective effects of curcumin, 197\nBecher, 1998, CD95–CD95L: can the brain learn from the immune system?, Trends Neurosci, 21, 114, 10.1016\u002FS0166-2236(97)01180-6\nSessler, 2013, Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling, Pharmacol Ther, 140, 186, 10.1016\u002Fj.pharmthera.2013.06.009\nItoh, 1991, The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis, Cell, 66, 233, 10.1016\u002F0092-8674(91)90614-5\nChoi, 2004, Fas ligand\u002FFas system in the brain: regulator of immune and apoptotic responses, Brain Res Rev, 44, 65, 10.1016\u002Fj.brainresrev.2003.08.007\nSuzuki, 1998, Rapid and specific reactive oxygen species generation via NADPH oxidase activation during Fas-mediated apoptosis, FEBS Lett, 425, 209, 10.1016\u002FS0014-5793(98)00228-2\nMasuda, 2002, Structural identification of new curcumin dimers and their contribution to the antioxidant mechanism of curcumin, J Agric Food Chem, 50, 2524, 10.1021\u002Fjf011601s\nNurfina, 1997, Synthesis of some symmetrical curcumin derivatives and their antiinflammatory activity, Eur J Med Chem, 32, 321, 10.1016\u002FS0223-5234(97)89084-8\nSreejayan, 1997, Inhibition of radiation-induced lipid peroxidation by curcumin, Int J Pharm, 151, 127, 10.1016\u002FS0378-5173(97)04900-4\nSharma, 1976, Antioxidant activity of curcumin and related compounds, Biochem Pharmacol, 25, 1811, 10.1016\u002F0006-2952(76)90421-4\nPriyadarsini, 2003, Role of phenolic OH and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin, Free Radic Biol Med, 35, 475, 10.1016\u002FS0891-5849(03)00325-3\nMiriyala, 2007, Cardioprotective effects of curcumin, 359\nSandur, 2007, Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane), Free Radic Biol Med, 43, 568, 10.1016\u002Fj.freeradbiomed.2007.05.009\nGalati, 2002, Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics, Toxicology, 177, 91, 10.1016\u002FS0300-483X(02)00198-1\nCifone, 1995, Multiple pathways originate at the Fas\u002FAPO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal, EMBO J, 14, 5859, 10.1002\u002Fj.1460-2075.1995.tb00274.x\nLi, 1999, Deciphering the pathways of life and death, Curr Opin Cell Biol, 11, 261, 10.1016\u002FS0955-0674(99)80035-0",{"EN":759},"Curcumin Inhibits Apoptosis and Brain Edema Induced by Hypoxia-Hypercapnia Brain Damage in Rat Models",{"VOID":761},"10.1097\u002Fmaj.0000000000000457","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0002962915300161",[764],{"id":765,"sortIndex":19,"researcher":18,"roles":766,"affiliations":767,"properties":768},"e85dd325-4a20-4fe9-8cc0-7a8bc66c96ff",[118],[],{"title":769},{"VI":770},"Linsheng Yu",{"url":762,"publisher":772,"properties":794},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":773,"slug":10,"properties":774,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":777,"manageAffiliations":778,"indexDatabases":779,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":775,"title":776},{"VOID":13},{"EN":15},[],[],[780,787],{"id":74,"indexDatabase":781,"url":87,"indexYears":88,"academicFieldIds":786,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":782,"label":783,"description":784,"key":84,"publicationTags":785,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":788,"url":70,"indexYears":18,"academicFieldIds":793,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":789,"label":790,"description":791,"key":66,"publicationTags":792,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":795,"pages":797},{"VOID":796},"349",{"VOID":798},"521-525","2015-06-01",2015,{"id":802,"createTime":803,"updateTime":804,"relativeEntities":805,"slug":806,"properties":807,"entityType":109,"verifyStatus":110,"verifyTime":804,"verifyNote":111,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":814,"fullTextUrl":18,"authors":815,"publicationType":156,"publisherRelationship":870,"citationCount":18,"citationInfo":18,"publishDate":897,"publishYear":748,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":187},"bb194bec-dfd8-4f42-96ba-f483b4b0c088","2024-02-12T18:53:02.657+00:00","2025-01-06T23:54:07.315+00:00",[],"Hemodynamic-and-Neurohormonal-Changes-in-the-Development-of-DOC-Hypertension-in-the-Dog",{"references":808,"title":810,"doi":812},{"VOID":809},"Selye, 1943, Malignant hypertension produced by treatment with desoxycorticosterone acetate and sodium chloride, Can Med Assoc J, 49, 88\nPage, 1987, 592\nPerera, 1951, Altered metabolic response prior to the development of hypertensive vascular disease, Am Heart J, 42, 308, 10.1016\u002F0002-8703(51)90249-9\nScoggins, 1982, A review of mechanisms involved in the production of steroid hypertension with particular reference to ACTH dependent hypertension, 41\nFerrario, 1981, An analytical description of the role of neurogenic factors in the control of arterial pressure, 185\nSzilagyi, 1981, Neurogenic suppression of carotid sinus reflexes by vagal afferents in sodium depleted dogs, Am J Physiol, 241, H255\nTramposch, 1984, Reduced role of cardiopulmonary receptors in modulation of carotid sinus reflexes in sodium loaded dogs, abstract, Physiologist, 27, 283\nFolkow, 1982, Physiological aspects of primary hypertension, Physiol Reu, 62, 347, 10.1152\u002Fphysrev.1982.62.2.347\nFerrario, 1987, Sodium balance and the reflex regulation of baroreflex function, Circulation, 75, I141\nFerrario, 1972, Cardiovascular effects of angiotensin mediated by central nervous system, Circ Res, 30, 257, 10.1161\u002F01.RES.30.3.257\nGanten, 1984, Brain angiotensin: on the way to becoming a well studied neuropeptide system, Biochem Pharmacol, 33, 3523, 10.1016\u002F0006-2952(84)90132-1\nBrody, 1980, Neural mechanism in hypertension, Annu Rev Physiol, 42, 441, 10.1146\u002Fannurev.ph.42.030180.002301\nMann, 1978, Effect of central and peripheral angiotensin blockade in hypertensive rats, Am J Physiol, 234, H629\nIgarashi, 1985, Depressor effects of captopril in DOCA-salt hypertensive rats: role of vasopressin, J Hypertens, 3, 149, 10.1097\u002F00004872-198504000-00007\nItaya, 1986, Central renin-angiotensin system and the pathogenesis of DOCA-salt hypertension in rats, Am J Physiol, 251, H261\nMohring, 1977, Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension, Am J Physiol, 232, F260\nCrofton, 1979, The importance of vasopressin in the development and maintenance of DOCA-salt hypertension in the rats, Hypertension, 1, 31, 10.1161\u002F01.HYP.1.1.31\nRabito, 1981, Evidence against a role of vasopressin in the maintenance of high blood pressure in mineralocorticoid and renovascular hypertension, Hypertension, 3, 34, 10.1161\u002F01.HYP.3.1.34\nYamamoto, 1984, Cardiovascular haemodynamics and vasopressin blockade in DOCA-salt hypertensive rats, Hypertension, 6, 397, 10.1161\u002F01.HYP.6.3.397\nBurnier, 1983, Alpha and beta adrenoceptor blockade in normotensive and deoxycorticosterone (DOC)-hypertensive rats: plasma vasopressin and vasopressin pressor effect, J Pharmacol Exp Ther, 224, 222\nRascher, 1983, Vasopressin in deoxycorticosterone acetate hypertension of rats: a haemodynamic analysis, J Cardiovasc Pharmacol, 5, 418, 10.1097\u002F00005344-198305000-00011\nMatsuguchi, 1982, Pressor response to vasopressin and impaired baroreflex function in DOC-salt hypertension, Am J Physiol, 242, H44\nMatsuguchi, 1982, Acute interaction of vasopressin and neurogenic mechanisms in DOCA-salt hypertension, Am J Physiol, 242, H37\nEguchi, 1983, Effect of potassium (K+) repletion on blood pressure (MAP) responses of dogs and man with mineralocorticoid-induced hypertension, abstract, Clin Res, 31, 329A\nUeno, 1988, Characteristics of hormonal and neurogenic mechanisms of DOC-induced hypertension, Hypertension, 11, I172, 10.1161\u002F01.HYP.11.2_Pt_2.I172\nMohara, 1987, Potentiation of baroreceptor reflexes during the early phase of steroid-hypertension, abstract, Physiologist, 30, 186\nBravo, 1977, Multifactorial analysis of chronic hypertension induced by electrolyte-active steroids in trained, unanesthetized dogs, Circ Res, 40, I140\nConway, 1978, Development of deoxycorticosterone acetate hypertension in the dog, Circ Res, 43, I82\nFerrario, 1979, Physiological and pharmacological characterization of the area postrema pressor pathways in the normal dog, Hypertension, 1, 235, 10.1161\u002F01.HYP.1.3.235\nBallard, 1960, Effects of aldosterone and plasma extracts on a rat heart-lung preparation, Am J Physiol, 199, 221, 10.1152\u002Fajplegacy.1960.199.2.221\nTanz, 1962, Studies on the inotropic action of aldosterone on isolated cardiac tissue preparation; including the effects of PH, ouabain and SC-8109, J Pharmacol Exp Ther, 135, 71\nBahler, 1971, Cardiovascular function in potassium- depleted dogs, Am Heart J, 81, 650, 10.1016\u002F0002-8703(71)90008-1\nMiller, 1979, Hemodynamic responses to DOCA in young pigs, Hypertension, 1, 591, 10.1161\u002F01.HYP.1.6.591\nFerrario, 1978, Current views concerning cardiac output in the genesis of experimental hypertension, Circ Res, 43, 821, 10.1161\u002F01.RES.43.6.821\nTerris, 1976, Desoxycorticosterone hypertension in the pig, Clinical Science and Molecular Medicine, 51, 303s\nHamlyn, 1986, Sodium chloride, extracellular fluid volume, and blood pressure regulation, Am J Physiol, 251, F563\nRuiz, 1983, Angiotensin concentration in the cerebrospinal fluid in different experimental conditions in the rat, Hypertension, 5, V29, 10.1161\u002F01.HYP.5.6_Pt_3.V29\nBasso, 1982, Regional distribution of angiotensinogen in the central nervous system of the rat: effect of DOC-salt treatment, Clin Sci, 63, 149s, 10.1042\u002Fcs063149s\nBasso, 1985, The brain renin-angiotensin system and the development of DOC-salt hypertension, Clin Exp Hypertens, A7, 1259\nSuzuki, 1983, Alterations in plasma and cerebrospinal fluid norepinephrine and angiotensin II during the development of renal hypertension in conscious dogs, Hypertension, 5, I139, 10.1161\u002F01.HYP.5.2_Pt_2.I139\nSuzuki, 1985, Nonrenal factors contribute to plasma and cerebrospinal fluid angiotensin II, Hypertension, 8, I95\nBerecek, 1982, Vasopressin-central nervous system interactions in the development of DOCA hypertension, Hypertension, 4, II131\nOkuno, 1983, Central catecholamine depletion, vasopressin, and blood pressure in the DOCA\u002FNaCl rat, Am J Physiol, 244, H807\nPhilipp, 1982, Mechanism of mineralocorticoid-induced hypertension in man, 129\nTakeda, 1980, Augmented sympathetic nerve activity and pressor responsiveness in DOCA hypertensive rats, Hypertension, 2, 97, 10.1161\u002F01.HYP.2.1.97\nHinke, 1965, In-vitro demonstration of vascular hyperresponsiveness in experimental hypertension, Circ Res, 17, 359, 10.1161\u002F01.RES.17.4.359\nBerecek, 1977, Structural and functional changes in vascular resistance and reactivity in the desoxycorticosterone acetate (DOCA) hypertensive pig, Circ Res, 40, I146\nSchmid, 1966, Effects of 9α-fluorohy-drocortisone on forearm vascular responses to norepinephrine, Circulation, 34, 620, 10.1161\u002F01.CIR.34.4.620\nBerecek, 1978, Whole body vascular reactivity during the development of desoxycorticosterone acetate hypertension in the pig, Circ Res, 42, 764, 10.1161\u002F01.RES.42.6.764\nRascher, 1981, Plasma catecholamines, noradrenergic metabolism, and vascular response in desoxycorticosterone acetate hypertension of rats, Eur J Pharmacol, 75, 255, 10.1016\u002F0014-2999(81)90552-5\nBerecek, 1982, Vasopressin-central nervous system interactions in the development of DOCA hypertension, Hypertension, 4, II131\nLumbers, 1979, Inhibition by angiotensin II of baroreceptor-evoked activity in cardiac vagal efferent nerves in the dog, J Physiol (Lond), 294, 69, 10.1113\u002Fjphysiol.1979.sp012915\nLumbers, 1983, Inhibition of the vagal component of the baroreceptor-cardioinhibitory reflex by angiotensin III in dogs and sheep, J Physiol (Lond), 336, 83, 10.1113\u002Fjphysiol.1983.sp014568\nHull, 1985, Central angiotensin II augments baroreflex gain in conscious dog, abstract, Circulation, 72, III18\nMouw, 1971, Central action of angiotensin in stimulating ADH release, Am J Physiol, 220, 239, 10.1152\u002Fajplegacy.1971.220.1.239\nCowley, 1984, Influence of vasopressin and angiotensin on baroreflexes in the dog, Circ Res, 54, 163, 10.1161\u002F01.RES.54.2.163\nBennett, 1986, Influence of exogenous vasopressin on baroreflex mechanism, Clin Sci, 70, 307, 10.1042\u002Fcs0700307\nCourtice, 1984, Excitation of the cardiac vagus by vasopressin in mammals, J Physiol (Lond), 354, 547, 10.1113\u002Fjphysiol.1984.sp015392",{"EN":811},"Hemodynamic and Neurohormonal Changes in the Development of DOC Hypertension in the Dog",{"VOID":813},"10.1097\u002F00000441-198804000-00023","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0002962915365812",[816,831,843,855],{"id":817,"sortIndex":116,"researcher":18,"roles":818,"affiliations":819,"properties":828},"a786b6ff-d0ee-4a0e-8171-da1a46aea962",[118],[820],{"id":18,"sortIndex":19,"affiliation":821,"properties":18},{"id":822,"createTime":823,"updateTime":823,"relativeEntities":824,"slug":18,"properties":825,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"bf8551fb-a820-434a-be66-ce8c725a50ef","2024-02-12T18:53:02.700+00:00",[],{"title":826},{"VI":827},"Department of Brain and Vascular Research, The Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio",{"title":829},{"VI":830},"O. Mohara",{"id":832,"sortIndex":248,"researcher":18,"roles":833,"affiliations":834,"properties":840},"6426ebbb-66d6-4a79-8e3a-8303efa0c1a6",[118],[835],{"id":18,"sortIndex":19,"affiliation":836,"properties":18},{"id":822,"createTime":823,"updateTime":823,"relativeEntities":837,"slug":18,"properties":838,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":839},{"VI":827},{"title":841},{"VI":842},"K.B. Brosnihan",{"id":844,"sortIndex":19,"researcher":18,"roles":845,"affiliations":846,"properties":852},"a530b892-c585-4d50-9fec-cb949de46f61",[118],[847],{"id":18,"sortIndex":19,"affiliation":848,"properties":18},{"id":822,"createTime":823,"updateTime":823,"relativeEntities":849,"slug":18,"properties":850,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":851},{"VI":827},{"title":853},{"VI":854},"C.M. Ferrario",{"id":856,"sortIndex":133,"researcher":18,"roles":857,"affiliations":858,"properties":867},"b8acbf6e-f9dd-4ce5-9c5c-24220c8a8ba7",[118],[859],{"id":18,"sortIndex":19,"affiliation":860,"properties":18},{"id":861,"createTime":862,"updateTime":862,"relativeEntities":863,"slug":18,"properties":864,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"d56f5393-8e81-4eb1-949a-4f9cd8839ed1","2024-02-12T18:53:02.756+00:00",[],{"title":865},{"VI":866},"Division of Cardiology, Wakayama Medical College, Wakayama, Japan",{"title":868},{"VI":869},"Y. Ueno",{"url":814,"publisher":871,"properties":893},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":872,"slug":10,"properties":873,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":876,"manageAffiliations":877,"indexDatabases":878,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":874,"title":875},{"VOID":13},{"EN":15},[],[],[879,886],{"id":74,"indexDatabase":880,"url":87,"indexYears":88,"academicFieldIds":885,"indexDatabaseRanking":91},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":881,"label":882,"description":883,"key":84,"publicationTags":884,"standard":18},[],{"EN":81,"VI":81},{"EN":81,"VI":83},[86],[90],{"id":55,"indexDatabase":887,"url":70,"indexYears":18,"academicFieldIds":892,"indexDatabaseRanking":18},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":888,"label":889,"description":890,"key":66,"publicationTags":891,"standard":18},[],{"EN":62,"VI":62},{"VI":64,"EN":65},[68,69],[72],{"volume":894,"pages":895},{"VOID":744},{"VOID":896},"352-359","1988-04-01"]